Kyverna Therapeutics, Inc. (KYTX)

Kyverna Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022
Net Income	-158.7	-127.48	-60.37	-28.89
Depreciation & Amortization	2.14	2.13	1.71	1.05
Stock-Based Compensation	9.47	8.36	2.22	0.93
Other Adjustments	-6.31	-5.12	0.61	1.13
Changes in Accounts Payable	4.96	0.74	4.08	0.68
Changes in Accrued Expenses	11.55	12.98	4.06	-1.37
Changes in Unearned Revenue	-	-	-	-7.03
Changes in Other Operating Activities	-5.18	-5.86	-4.72	-2.61
Operating Cash Flow	-141.41	-114.25	-52.41	-36.11
Capital Expenditures	-0.64	-2.21	-0.62	-0.77
Purchases of Investments	-440.62	-490	-54.85	-56.5
Proceeds from Sale of Investments	506.1	331.3	46.68	43.17
Investing Cash Flow	64.64	-160.9	-8.79	-14.1
Issuance of Common Stock	-	341.43	0.65	0.18
Net Common Stock Issued (Repurchased)	-	341.43	0.65	0.18
Issuance of Preferred Stock	-	-	59.9	11.95
Net Preferred Stock Issued (Repurchased)	-	-	59.9	11.95
Other Financing Activities	-1.09	-4.32	-2.43	-0.25
Financing Cash Flow	-1.43	337.11	58.12	11.88
Net Cash Flow	-78.2	61.96	-3.08	-38.33
Beginning Cash & Cash Equivalents	132.19	35.21	38.29	76.62
Ending Cash & Cash Equivalents	53.99	97.17	35.21	38.29
Free Cash Flow	-142.05	-116.46	-53.03	-36.88
FCF Margin	-	-	-	-525.00%
Free Cash Flow Per Share	-3.29	-3.04	-78.73	-80.97
Levered Free Cash Flow	-145.87	-119.69	-55.86	-38.94
Unlevered Free Cash Flow	-158.8	-134.82	-57.9	-39.43

Updated Jun 30, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q